NorthWest Biotherapeutics Inc (NWBO)

[WideEyed]

Kabunushi,

Against my better judgement I’m going to reply to your post. I can think of more than 30 or 40 Longs who are much better qualified to reply but they all probably have you on ignore or they have better things to do than to reply to your posts. I saw Lykiri’s post to you saying that Dr Ashkan had never used DCVax-L + poly-iclc and your reaction was like one of confirmation that dstock didn’t know what he was talking about because he said something to the effect “probably more than a thousand patients had been treated with DCVax-L + poly-iclc”. So, yes, it’s true the data doesn’t support dstock’s assertion but in principle he’s correct. How so? Poly-iclc doesn’t have regulatory approval which is probably why Dr Ashkan hasn’t used it. But you can bet your bottom dollar he probably used something in its place that has regulatory approval; something from the same category. Poly-iclc is a TLR; looking on the internet, another TLR is TLR4 agonist (Monophosphoryl lipid A (MPLA) ). So, Dr Ashkan used a different TLR. It’s the same thing as using different Checkpoint Inhibitors; Keytruda or Opdivo or Tecentriq, take your pick they’re all Checkpoint Inhibitors and the efficacy varies a little between them; but they all are effective. Ditto for the TLRs. So, the UK Specials program has more than a thousand data points (patients) with DCVax-L + TLR + Checkpoint Inhibitor, which backs up dstock in principle. When Linda Liau gives her Bench to Bedside presentation on Oct 14 it’s most likely going to include the more than thousand data points from the Specials program. When she presents the data and if we’re quiet enough I imagine we’ll hear a collective “WoW!!!” from 11,000 neurologists from around the world. This will most certainly motivate them to use DCVax-L + TLR + Checkpoint Inhibitor; Sawston is going to be like Mecca and quickly approach manual capacity. No, the TLR in (DCVax-L + TLR + Checkpoint Inhibitor) won’t be poly-iclc but that doesn’t really change anything in principle; it SO doesn’t change anything that I’m keeping my 2026 end of year NWBO stock price estimates of $36 or $39. Oh, one last thing. You keep pumping everyone to show you the data, well, LL will show you enough data on Oct 14 for you to put it in your pipe and smoke it until the apocalypse.